Table 1.
Patient characteristics of the three orthogonal cohorts used in this study: multimodal, radiology and pathology
| Characteristics | Multimodal | Radiology | Pathology |
|---|---|---|---|
| (n = 247) | (n = 50) | (n = 52) | |
| n (%) | n (%) | n (%) | |
| Age, median (range) | 68 (38–93) | 67 (45–86) | 71 (30–89) |
| Sex | |||
| Male | 113 (46) | 24 (48) | 23 (44) |
| Female | 134 (54) | 26 (52) | 29 (56) |
| Performance status | |||
| ECOG 0/1 | 222 (90) | 25 (50) | 49 (94) |
| ECOG ≥2 | 25 (10) | 25 (50) | 3 (6) |
| Smoking status | |||
| Current/former | 218 (88) | 38 (76) | 47 (90) |
| Never | 29 (12) | 12 (24) | 5 (10) |
| Histology | |||
| Adenocarcinoma | 195 (79) | 39 (78) | 32 (62) |
| Squamous | 37 (15) | 8 (16) | 11 (21) |
| Large cell | 7 (3) | 2 (4) | 0 (0) |
| NSCLC, NOS | 8 (3) | 1 (2) | 9 (17) |
| Line of therapy | |||
| 1 | 78 (32) | 5 (10) | 35 (67) |
| 2 | 136 (55) | 24 (48) | 11 (21) |
| ≥3 | 33 (13) | 21 (42) | 6 (12) |
| Therapy type | |||
| Anti-PD-(L)1 monotherapy | 235 (95) | 48 (96) | 52 (100) |
| Anti-PD-(L)1 + CTLA-4 combination | 12 (5) | 2 (4) | 0 (0) |
| PD-L1 expression | |||
| 0 | 114 (46) | – | 0 (0) |
| 1–49% | 51 (21) | – | 13 (25) |
| ≥50% | 82 (33) | – | 39 (75) |
| Tissue site | – | ||
| Lung | 109 (44) | – | 25 (48) |
| Pleura/pleural fluid | 19 (8) | – | 1 (2) |
| Lymph node | 45 (18) | – | 10 (19) |
| Liver | 11 (4) | – | 2 (4) |
| Bone | 16 (7) | – | 3 (6) |
| Adrenal | 11 (4) | – | 1 (2) |
| Other | 36 (15) | 10 (19) | |
| TMB | |||
| ≥10 mutations per Mb | 155 (63) | 9 (29) | 22 (58) |
| <10 mutations per Mb | 92 (37) | 22 (71) | 16 (42) |
| Best overall response | |||
| CR/PR | 62 (25) | 11 (22) | 14 (27) |
| SD/PD | 185 (75) | 39 (78) | 38 (73) |
ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified.